Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
ASCO 2016 – Lung Cancer
Various therapeutic strategies are available for non–small-cell lung cancer (NSCLC) patients who develop disease progression on first-line EGFR tyrosine kinase inhibitor (TKI) therapy. However, it has not been established which cytotoxic regimens are preferable for these patients. Yoo and colleagues conducted a prospective randomized phase 2 trial to assess the clinical outcomes with pemetrexed plus cisplatin (PC) combination therapy compared with pemetrexed monotherapy after failure of first-line EGFR TKI.
1
Patients with advanced (stage IIIB) or metastatic (stage IV) nonsquamous NSCLC harboring activating
EGFR
mutation (del 19 or
L858R
mutation) who had progressed on first-line EGFR TKI were randomly assigned in a ratio of 1:1 to the PC arm or pemetrexed arm, and were treated with pemetrexed 500 mg/m
2
and cisplatin 70 mg/m
2
for 4 cycles, followed by pemetrexed maintenance every 3 weeks, or treated with pemetrexed 500 mg/m
2
monotherapy every 3 weeks until progression of disease. The primary clinical end point was progression-free survival (PFS), and secondary end points included overall response rate, overall survival, quality of life (QOL), and the safety profile. A total of 96 patients were randomized, and 91 patients were treated. At 20.4 months of median follow-up, the median PFS was 5.4 months (95% confidence interval [CI], 4.5-6.3) in the PC arm and 6.4 months (95% CI, 3.6-9.2) in the pemetrexed arm (
P
= 0.313). The 1-year survival rate was 77% for the PC arm and 68% for the pemetrexed arm. The most common adverse events included anorexia (37%), nausea (26%), neuropathy (11%), and skin change (11%). Adverse events ≥grade 3 were in 12 (26%) patients in the PC arm and 8 (18%) patients in the pemetrexed arm, and dose reduction and delay were required more often in the PC arm. The authors concluded that PC combination therapy showed a higher response rate than pemetrexed monotherapy. However, there was no significant difference in PFS between the 2 arms, and that further genetic and molecularly based analyses are warranted to evaluate the contributing factors for long-term responders. While the authors promised that QOL data would be presented at ASCO 2016, QOL analyses were not available at the meeting.
Yoo KH, et al. ASCO 2016. Abstract 9043.
Related Items
IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Utilizing Chemotherapy to Treat Lung Cancer
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us